ROHTO Pharmaceutical Launches an AI Project Using Microsoft AI Co-Innovation Lab
- A Customers-AI Co-innovation Project to Celebrate the 135th Anniversary of The Mentholatum Company -
Feb 8, 2024
ROHTO Pharmaceutical Co., Ltd. (Osaka City, Osaka Prefecture; President: Masashi Sugimoto) is pleased to announce that in January 2024, the company started a project, through the Microsoft AI Co-Innovation Lab (Kobe City, Hyogo Prefecture; Head of Microsoft AI Co-Innovation Lab Kobe: Takehiro Hirai), that analyzes and consolidates the voice of the customer with generative AI to create new value.
The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, has a network of customers in more than 110 countries around the world, and we use generative AI to analyze and consolidate the customer feedback that we have received about us and our products through the customer network to generate new expressions.
To make a positive contribution to the well-being of our customers all over the world, we are committed to actively using technologies to create new value.
Background and details of this project
Founded in 1889, The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, has served customers in more than 110 countries around the world. Our brand has grown over the years as we have supported and connected with our customers around the world and listened to their problems. We have received hundreds of thousands of comments from them about us and our products.
In this project, we are using Microsoft Azure OpenAI Service, to create new value by analyzing "emotional" information contained in customer feedback through the simultaneous consolidation of multiple languages using AI. As we celebrate the 135th anniversary of The Mentholatum Company, in the first phase of the project, we will generate new images as an expression of connecting to the future based on the feedback from our loyal customers.
Masaya Saito, Executive Vice President and CFO of ROHTO Pharmaceutical
Co., Ltd. and President of The Mentholatum Company
We are confident that generative AI is effective in helping us capture
a vast number of customer comments that are beyond human comprehension
and apply them to the development of products and services for future generations.
In this project, we use Azure OpenAI Service at Microsoft AI Co-Innovation
Lab in Kobe and simultaneously consolidate multiple languages and connect
with "customers' emotions" found in their comments, and we hope
to increase the value of Mentholatum products that we market worldwide.
Mr. Jun Yamasaki, Head of Microsoft AI Co-Innovation Labs, Microsoft Corporation
This project is undertaken with the technical support provided by Microsoft
AI Co-Innovation Lab ("Kobe Lab"), which is a new facility opened
in Kobe Japan. I am thrilled that the innovative services Kobe Lab and
Microsoft Azure provide, including Azure OpenAI Service, are helping ROHTO
Pharmaceutical carry out this project and that Kobe will be the birthplace
of a new form of AI co-innovation that will be showcased to the rest of
the world.